(SMMT)
NGM – Real Time Price. Currency in USD
16.58
-0.68 (-3.94%)
At close: Mar 27, 2026, 4:00 PM EDT
16.43
-0.15 (-0.90%)
After-hours: Mar 27, 2026, 7:59 PM EDT
Get all premium features to the best stock analysis tool
NGM – Real Time Price. Currency in USD
16.58
-0.68 (-3.94%)
At close: Mar 27, 2026, 4:00 PM EDT
16.43
-0.15 (-0.90%)
After-hours: Mar 27, 2026, 7:59 PM EDT
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.
| Name | Position |
|---|---|
| Dr. Allen S. Yang M.D., Ph.D. | Head of R&D Strategy |
| Dr. Mahkam Zanganeh D.D.S., M.B.A. | Co-CEO, President & Director |
| Dr. Urte Gayko Ph.D. | Chief Regulatory, Quality & Pharmacovigilance Officer |
| Dr. Wang Clow Fong ScD | Chief Biometrics Officer |
| Mr. Bhaskar Anand | Chief Accounting Officer |
| Mr. Dave Gancarz | Chief Business & Strategy Officer |
| Mr. Manmeet Singh Soni CPA | COO, CFO & Director |
| Date | Type | Document |
|---|---|---|
| 2026-01-29 | 8-K | smmt-20260129.htm |
| 2026-01-12 | 8-K | smmt-20260112.htm |
| 2025-11-07 | 8-K | smmt-20251107.htm |
| 2025-10-29 | S-3ASR | d79902ds3asr.htm |
| 2025-10-22 | 8-K | d274712d8k.htm |
| 2025-10-20 | 8-K | smmt-20251017.htm |
| 2025-09-08 | 8-K | smmt-20250907.htm |
| 2025-08-11 | 8-K | smmt-20250811.htm |
| 2025-06-20 | 8-K | smmt-20250616.htm |
| 2025-06-17 | 8-K | smmt-20250612.htm |
| Mr. Nathan LiaBraaten |
| Senior Director of Investor Relations |
| Mr. Robert W. Duggan | Co-CEO & Executive Chairman |
| Prof. Kay Elizabeth Davies DBE, FRS CBE | Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor |